192 results
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
6-K
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.
JonesTrading
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good … as if such payment had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
market, the liquidity of the pre-funded warrants will be limited.
The warrants are speculative in nature.
The warrants do not confer any rights … loss of the purchase price of their warrants. This risk reflects the nature of a warrant as an asset that, other factors held constant, tends
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
have a material adverse impact on our liquidity, business, financial condition and results of operations. In addition, depending on the nature and timing … of law.
Our technology may infringe the rights of third parties. The nature of claims contained in unpublished patent filings around the world
F-3
suw0k2cjxu
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
ok5m7 sbrn
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
vkyjffus 98
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
a5mc7t3b2pz7sj29ji
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
6qq4j4g2u ow5yyz1bv
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
6wl qn0uepftzy9
30 Aug 23
Current report (foreign)
6:45am
6-K
07w64i8du3999eigpo
8 Aug 23
Current report (foreign)
5:25pm
6-K
EX-99
2shkoirnk
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
hexk4lo
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
hvrn8t1 hq
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
1hyd9s0 h2xj5
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
rgs6gpab5
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
q62m64 95gypwjpi90o
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
bs2vcfps4s0ula4js1
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am